
Solasta Ventures is a venture capital firm and wholly-owned subsidiary of Aju IB Investment, focused on investing in innovative companies that advance the standard of care for diseases with unmet medical needs, particularly in therapeutics and discovery platforms.
32% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (58% of deals). Average disclosed round size is $64.9M (across 17 rounds with reported amounts).
Portfolio
18
Fund Size
—
Top Stage
Series B
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
19 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Series A | $14M | Dec 2025 | |
| MMaxion Therapeutics Ltd. | Series A | $72M | Jan 2025 |
| Series A | $115M | Oct 2024 | |
| AAxonis Therapeutics | Series A | $115M | Jan 2024 |
| Series B | $135M | May 2023 | |
| Series B | $30M | May 2023 | |
| Series A | $38M | Jun 2022 | |
| Series B | $70M | Feb 2022 | |
| Series B | $58M | Aug 2021 | |
| IImmunitas | Series B | $58M | Aug 2021 |
| CCarisma Therapeutics, Inc. | Series B | — | Mar 2021 |
| IImmunitas | Series B | $58M | Jan 2021 |
| RRideCell, Inc | Series C | $45M | Dec 2020 |
| Series B | $65M | May 2020 | |
| Series B | $50M | — | |
| Growth | — | — | |
| Series A | $72M | — | |
| RReCode | Series B | $50M | — |
| Series B | $59M | — |
Top Co-Investors
Agent Capital6 shared
MRL Ventures Fund5 shared
Alexandria Venture Investments5 shared
Mirae Asset4 shared
Leaps by Bayer4 shared
Cormorant Asset Management3 shared
Sofinnova Partners3 shared
AJU IB Investment3 shared
Longwood Fund3 shared
BrightEdge3 shared
M Ventures3 shared
Ono Venture Investment3 shared
Alumni Ventures2 shared
venBio2 shared
BoxOne Ventures2 shared
Perceptive Advisors2 shared
Tekla Capital Management2 shared
Sanofi Ventures2 shared
Colt Ventures2 shared
OrbiMed2 shared
Last updated: 9 September 2026